CRISPR Therapeutics AG (CRSP) Whale Options Tug-of-War, Max Pain & Unusual Sweeps
CRISPR Therapeutics AG (CRSP) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (55/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+61.2% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Active Strike Call vs. Put Concentration Ladder (CRSP)
Practice in Our Weekly $100,000 Prop Arena Before Risking Personal Capital
Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring CRSP)
- ✓Live walkthrough of CRSP's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
CRSP Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on CRSP today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for CRSP. Explore sector supply chains on /butterfly.
CRSP Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhat is CRSP's options max pain and whale flow sentiment?
Unusual options sweeps in CRSP show 55% bullish call premium versus 45% put premium, centered near a $53 max-pain strike.